Incyte Corp (INCY) stock
INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3082% above fair value
$120.39+3.59 (+3.07%)
Close on Oct 30, 2026Market cap $24.40BP/E 64.0Yield –
Earnings
Incyte's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$1.56B
+13.9% on a year earlier
Non-GAAP diluted EPS, Q3 FY2026
-$3.60
$2.26 a year earlier
Latest guidance
Raised
Oct 29, 2026 · 6 items
Quarterly results
Revenue and earnings per share from each of Incyte's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 9, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026before the open | $1.56B | +13.9% | -$3.86 | -$3.60 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 28, 2026before the open | $1.67B | +37.3% | $2.81 | $3.09 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 28, 2026before the open | $1.27B | +20.9% | $1.47 | $1.81 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 10, 2026before the open | $1.51B | +25.8% | $1.46 | $1.80 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025before the open | $1.37B | +20.4% | $2.11 | $2.26 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025before the open | $1.22B | +16.5% | $2.04 | $1.57 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025before the open | $1.05B | +19.5% | $0.80 | $1.16 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 10, 2025before the open | $1.20B | +18.4% | $1.02 | $1.43 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024before the open | $1.14B | +23.8% | $0.54 | $1.07 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 30, 2024before the open | $1.04B | +9.4% | -$2.04 | -$1.82 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 30, 2024before the open | $881.00M | +8.9% | $0.75 | $0.64 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 13, 2024before the open | $1.01B | +9.3% | $0.89 | $1.06 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 31, 2023before the open | $919.00M | +11.6% | $0.76 | $1.10 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023before the open | $954.61M | +4.8% | $0.90 | $0.99 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 2, 2023before the open | $808.67M | – | $0.10 | $0.37 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 7, 2023before the open | $926.70M | – | $0.13 | $0.62 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 1, 2022before the open | $823.30M | – | $0.50 | $0.60 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022before the open | $911.00M | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022before the open | – | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 8, 2022before the open | – | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021before the open | – | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 3, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 9, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Incyte's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total net sales | FY2026 | $5.13B – $5.26B | $800.00M – $880.00M | Raised | Jul 28, 2026 |
| Total net sales | FY2026 | $5.21B – $5.30B | – | New | Oct 29, 2026 |
| Hematology and Oncology net sales | FY2026 | $890.00M – $910.00M | – | Lowered | Oct 29, 2026 |
| Hematology and Oncology net sales | FY2026 | $860.00M – $890.00M | – | Lowered | Jul 28, 2026 |
| Jakafi net sales | FY2026 | $3.22B – $3.27B | – | Raised | Oct 29, 2026 |
| Jakafi net sales | FY2026 | $3.22B – $3.27B | – | New | Jul 28, 2026 |
| Opzelura net sales | FY2026 | $1.10B – $1.12B | – | New | Oct 29, 2026 |
| Opzelura net sales | FY2026 | $1.05B – $1.10B | – | Lowered | Jul 28, 2026 |
| Total GAAP R&D and SG&A operating expenseGAAP | FY2026 | $4.92B – $5.00B | – | Raised | Jul 28, 2026 |
| Total GAAP R&D and SG&A operating expensesGAAP | FY2026 | $4.92B – $5.00B | – | New | Oct 29, 2026 |
| Total GAAP R&D and SG&A operating expensesGAAP | FY2026 | $3.50B – $3.68B | $3.50B – $3.68B | Reaffirmed | Apr 28, 2026 |
| total non-GAAP R&D and SG&A operating expensenon-GAAP | FY2026 | $4.63B – $4.70B | – | Raised | Jul 28, 2026 |
| Total Non-GAAP R&D and SG&A operating expensesnon-GAAP | FY2026 | $4.63B – $4.70B | – | New | Oct 29, 2026 |
| Total Non-GAAP R&D and SG&A operating expensesnon-GAAP | FY2026 | $3.21B – $3.38B | $3.21B – $3.38B | Reaffirmed | Apr 28, 2026 |
Guidance vs results
The last range Incyte gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $4.23B – $4.32B | $5.15BΣ4Q | Above range |
Guidance history
Every forecast Incyte put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Opzelura net sales | FY2026 | $1.10B – $1.12B | New |
| Oct 29, 2026 | Jakafi net sales | FY2026 | $3.22B – $3.27B | Raised |
| Oct 29, 2026 | Hematology and Oncology net sales | FY2026 | $890.00M – $910.00M | Lowered |
| Oct 29, 2026 | Total GAAP R&D and SG&A operating expenses | FY2026 | $4.92B – $5.00B | New |
| Oct 29, 2026 | Total Non-GAAP R&D and SG&A operating expenses | FY2026 | $4.63B – $4.70B | New |
| Oct 29, 2026 | Total net sales | FY2026 | $5.21B – $5.30B | New |
| Jul 28, 2026 | Opzelura net sales | FY2026 | $1.05B – $1.10B | Lowered |
| Jul 28, 2026 | Jakafi net sales | FY2026 | $3.22B – $3.27B | New |
| Jul 28, 2026 | Hematology and Oncology net sales | FY2026 | $860.00M – $890.00M | Lowered |
| Jul 28, 2026 | Total GAAP R&D and SG&A operating expense | FY2026 | $4.92B – $5.00B | Raised |
| Jul 28, 2026 | total non-GAAP R&D and SG&A operating expense | FY2026 | $4.63B – $4.70B | Raised |
| Jul 28, 2026 | total net sales | FY2026 | $5.13B – $5.26B | Raised |
| Apr 28, 2026 | Total GAAP R&D and SG&A operating expenses | FY2026 | $3.50B – $3.68B | Reaffirmed |
| Apr 28, 2026 | Total Non-GAAP R&D and SG&A operating expenses | FY2026 | $3.21B – $3.38B | Reaffirmed |
| Apr 28, 2026 | Hematology and Oncology net sales | FY2026 | $800.00M – $880.00M | Raised |
| Apr 28, 2026 | Total net sales | FY2026 | $4.77B – $4.94B | Raised |
| Apr 28, 2026 | Jakafi net sales | FY2026 | $3.22B – $3.27B | Lowered |
| Apr 28, 2026 | Opzelura net sales | FY2026 | $750.00M – $790.00M | Lowered |
| Feb 10, 2026 | Total GAAP R&D and SG&A operating expenses | FY2026 | $3.50B – $3.68B | New |
| Feb 10, 2026 | Total non-GAAP R&D and SG&A operating expenses | FY2026 | $3.21B – $3.38B | New |
| Feb 10, 2026 | Total net product revenue | FY2026 | $4.77B – $4.94B | New |
| Feb 10, 2026 | Jakafi net product revenue | FY2026 | $3.22B – $3.27B | Lowered |
| Feb 10, 2026 | Opzelura net product revenue | FY2026 | $750.00M – $790.00M | Lowered |
| Feb 10, 2026 | Hematology and Oncology net product revenue | FY2026 | $800.00M – $880.00M | Raised |
| Oct 28, 2025 | GAAP Cost of product revenues | FY2025 | 8% – 9% | Reaffirmed |
| Oct 28, 2025 | Non-GAAP Cost of product revenues | FY2025 | 7% – 8% | Reaffirmed |
| Oct 28, 2025 | GAAP Research and development expenses | FY2025 | $1.97B – $2.00B | Raised |
| Oct 28, 2025 | GAAP Selling, general and administrative expenses | FY2025 | $1.28B – $1.31B | Lowered |
| Oct 28, 2025 | Non-GAAP Research and development expenses | FY2025 | $1.82B – $1.84B | Raised |
| Oct 28, 2025 | Non-GAAP Selling, general and administrative expenses | FY2025 | $1.16B – $1.19B | Lowered |
| Oct 28, 2025 | net product revenue | FY2025 | $4.23B – $4.32B | Raised |
| Oct 28, 2025 | Jakafi net product revenues | FY2025 | $3.05B – $3.08B | Lowered |
| Oct 28, 2025 | other hematology and oncology marketed products | FY2025 | $550.00M – $575.00M | Lowered |
| Oct 28, 2025 | Opzelura ® (ruxolitinib) cream revenue | FY2025 | $630.00M – $670.00M | Raised |
| Jul 29, 2025 | GAAP Cost of product revenues | FY2025 | 8% – 9% | New |
| Jul 29, 2025 | Non-GAAP Cost of product revenues | FY2025 | 7% – 8% | New |
| Jul 29, 2025 | GAAP Research and development expenses | FY2025 | $1.97B – $2.00B | New |
| Jul 29, 2025 | GAAP Selling, general and administrative expenses | FY2025 | $1.28B – $1.31B | Lowered |
| Jul 29, 2025 | Non-GAAP Research and development expenses | FY2025 | $1.82B – $1.84B | New |
| Jul 29, 2025 | Non-GAAP Selling, general and administrative expenses | FY2025 | $1.16B – $1.19B | Lowered |
| Jul 29, 2025 | Jakafi net product revenues | FY2025 | $3.00B – $3.05B | New |
| Jul 29, 2025 | Opzelura net product revenues | FY2025 | $630.00M – $670.00M | Lowered |
| Jul 29, 2025 | Other oncology net product revenues | FY2025 | $500.00M – $520.00M | Lowered |
| Apr 29, 2025 | GAAP Cost of product revenues | FY2025 | 8.5% – 9% | Reaffirmed |
| Apr 29, 2025 | Non-GAAP Cost of product revenues | FY2025 | 7.5% – 8% | Reaffirmed |
| Apr 29, 2025 | GAAP Research and development expenses | FY2025 | $1.93B – $1.96B | Raised |
| Apr 29, 2025 | GAAP Selling, general and administrative expenses | FY2025 | $1.28B – $1.31B | Lowered |
| Apr 29, 2025 | Non-GAAP Research and development expenses | FY2025 | $1.78B – $1.81B | Raised |
| Apr 29, 2025 | Non-GAAP Selling, general and administrative expenses | FY2025 | $1.16B – $1.19B | Lowered |
| Apr 29, 2025 | Jakafi net product revenues | FY2025 | $2.95B – $3.00B | Raised |
| Apr 29, 2025 | Opzelura net product revenues | FY2025 | $630.00M – $670.00M | Lowered |
| Apr 29, 2025 | Other oncology net product revenues | FY2025 | $415.00M – $455.00M | Lowered |
| Feb 10, 2025 | GAAP Cost of product revenues | FY2025 | 8.5% – 9% | New |
| Feb 10, 2025 | Non-GAAP Cost of product revenues | FY2025 | 7.5% – 8% | New |
| Feb 10, 2025 | GAAP Research and development expenses | FY2025 | $1.93B – $1.96B | New |
| Feb 10, 2025 | GAAP Selling, general and administrative expenses | FY2025 | $1.28B – $1.31B | Lowered |
| Feb 10, 2025 | Non-GAAP Research and development expenses | FY2025 | $1.78B – $1.81B | New |
| Feb 10, 2025 | Non-GAAP Selling, general and administrative expenses | FY2025 | $1.16B – $1.19B | Lowered |
| Feb 10, 2025 | Jakafi net product revenues | FY2025 | $2.93B – $2.98B | New |
| Feb 10, 2025 | Opzelura net product revenues | FY2025 | $630.00M – $670.00M | Lowered |
| Feb 10, 2025 | Other oncology net product revenues | FY2025 | $415.00M – $455.00M | Lowered |
| Oct 29, 2024 | GAAP Cost of product revenues | FY2024 | 7% – 8% | Reaffirmed |
| Oct 29, 2024 | Non-GAAP Cost of product revenues | FY2024 | 6% – 7% | Reaffirmed |
| Oct 29, 2024 | GAAP Research and development expenses | FY2024 | $2.55B – $2.59B | Raised |
| Oct 29, 2024 | GAAP Selling, general and administrative expenses | FY2024 | $1.21B – $1.24B | Lowered |
| Oct 29, 2024 | Non-GAAP Research and development expenses | FY2024 | $2.40B – $2.44B | Raised |
| Oct 29, 2024 | Non-GAAP Selling, general and administrative expenses | FY2024 | $1.12B – $1.14B | Lowered |
| Oct 29, 2024 | Jakafi net product revenues | FY2024 | $2.74B – $2.77B | Raised |
| Oct 29, 2024 | Other Hematology/Oncology net product revenues | FY2024 | $310.00M – $320.00M | Lowered |
| Jul 30, 2024 | Non-GAAP Cost of product revenues (2) | FY2024 | 6% – 7% | Reaffirmed |
| Jul 30, 2024 | GAAP Research and development expenses | FY2024 | $1.76B – $1.80B | Raised |
| Jul 30, 2024 | GAAP Selling, general and administrative expenses | FY2024 | $1.21B – $1.24B | Lowered |
| Jul 30, 2024 | Non-GAAP Research and development expenses (3) | FY2024 | $1.62B – $1.66B | Raised |
| Jul 30, 2024 | Non-GAAP Selling, general and administrative expenses (3) | FY2024 | $1.12B – $1.14B | Lowered |
| Jul 30, 2024 | GAAP Cost of product revenues | FY2024 | 7% – 8% | Reaffirmed |
| Jul 30, 2024 | Jakafi net product revenues | FY2024 | $2.71B – $2.75B | Raised |
| Jul 30, 2024 | Other Hematology/Oncology net product revenues (1) | FY2024 | $325.00M – $360.00M | Lowered |
| Apr 30, 2024 | Non-GAAP Research and development expenses (3) | FY2024 | $1.58B – $1.62B | Raised |
| Apr 30, 2024 | GAAP Cost of product revenues | FY2024 | 7% – 8% | Reaffirmed |
| Apr 30, 2024 | Non-GAAP Cost of product revenues (2) | FY2024 | 6% – 7% | Reaffirmed |
| Apr 30, 2024 | GAAP Research and development expenses | FY2024 | $1.72B – $1.76B | Raised |
| Apr 30, 2024 | GAAP Selling, general and administrative expenses | FY2024 | $1.21B – $1.24B | Lowered |
| Apr 30, 2024 | Non-GAAP Selling, general and administrative expenses (3) | FY2024 | $1.12B – $1.14B | Lowered |
| Apr 30, 2024 | Other Hematology/Oncology net product revenues (1) | FY2024 | $325.00M – $360.00M | Lowered |
| Apr 30, 2024 | Jakafi net product revenues | FY2024 | $2.69B – $2.75B | Raised |
| Feb 13, 2024 | GAAP Cost of product revenues | FY2024 | 7% – 8% | New |
| Feb 13, 2024 | Non-GAAP Cost of product revenues (2) | FY2024 | 6% – 7% | New |
| Feb 13, 2024 | GAAP Research and development expenses | FY2024 | $1.72B – $1.76B | New |
| Feb 13, 2024 | GAAP Selling, general and administrative expenses | FY2024 | $1.21B – $1.24B | Lowered |
| Feb 13, 2024 | Non-GAAP Research and development expenses (3) | FY2024 | $1.58B – $1.62B | New |
| Feb 13, 2024 | Non-GAAP Selling, general and administrative expenses (3) | FY2024 | $1.12B – $1.14B | Lowered |
| Feb 13, 2024 | Jakafi net product revenues | FY2024 | $2.69B – $2.75B | New |
| Feb 13, 2024 | Other Hematology/Oncology net product revenues (1) | FY2024 | $325.00M – $360.00M | Lowered |
| Oct 31, 2023 | GAAP Cost of product revenues | FY2023 | 7% – 8% | Reaffirmed |
| Oct 31, 2023 | Non-GAAP Cost of product revenues (2) | FY2023 | 6% – 7% | Reaffirmed |
| Oct 31, 2023 | GAAP Research and development expenses | FY2023 | $1.61B – $1.65B | Raised |
| Oct 31, 2023 | GAAP Selling, general and administrative expenses | FY2023 | $1.05B – $1.15B | Lowered |
| Oct 31, 2023 | Non-GAAP Research and development expenses (3) | FY2023 | $1.49B – $1.52B | Raised |
| Oct 31, 2023 | Non-GAAP Selling, general and administrative expenses (3) | FY2023 | $965.00M – $1.06B | Lowered |
| Oct 31, 2023 | Jakafi net product revenues | FY2023 | $2.59B – $2.62B | Raised |
| Oct 31, 2023 | Other Hematology/Oncology net product revenues (1) | FY2023 | $215.00M – $225.00M | Lowered |
| Aug 1, 2023 | GAAP Cost of product revenues | FY2023 | 7% – 8% | Reaffirmed |
| Aug 1, 2023 | Non-GAAP Cost of product revenues (2) | FY2023 | 6% – 7% | Reaffirmed |
| Aug 1, 2023 | GAAP Research and development expenses | FY2023 | $1.61B – $1.65B | Raised |
| Aug 1, 2023 | GAAP Selling, general and administrative expenses | FY2023 | $1.05B – $1.15B | Lowered |
| Aug 1, 2023 | Non-GAAP Research and development expenses (3) | FY2023 | $1.49B – $1.52B | Raised |
| Aug 1, 2023 | Non-GAAP Selling, general and administrative expenses (3) | FY2023 | $965.00M – $1.06B | Lowered |
| Aug 1, 2023 | Jakafi net product revenues | FY2023 | $2.58B – $2.63B | Raised |
| Aug 1, 2023 | Other Hematology/Oncology net product revenues (1) | FY2023 | $215.00M – $225.00M | Lowered |
| May 2, 2023 | GAAP Cost of product revenues | FY2023 | 7% – 8% | Reaffirmed |
| May 2, 2023 | Non-GAAP Cost of product revenues | FY2023 | 6% – 7% | Reaffirmed |
| May 2, 2023 | GAAP Research and development expenses | FY2023 | $1.61B – $1.65B | Raised |
| May 2, 2023 | GAAP Selling, general and administrative expenses | FY2023 | $1.05B – $1.15B | Lowered |
| May 2, 2023 | Non-GAAP Research and development expenses | FY2023 | $1.49B – $1.52B | Raised |
| May 2, 2023 | Non-GAAP Selling, general and administrative expenses | FY2023 | $965.00M – $1.06B | Lowered |
| May 2, 2023 | Jakafi net product revenues | FY2023 | $2.55B – $2.63B | Raised |
| May 2, 2023 | Other Hematology/Oncology net product revenues | FY2023 | $215.00M – $225.00M | Lowered |
| Feb 7, 2023 | GAAP Cost of product revenues | FY2023 | 7% – 8% | New |
| Feb 7, 2023 | Non-GAAP Cost of product revenues (2) | FY2023 | 6% – 7% | New |
| Feb 7, 2023 | GAAP Research and development expenses | FY2023 | $1.61B – $1.65B | New |
| Feb 7, 2023 | GAAP Selling, general and administrative expenses | FY2023 | $1.05B – $1.15B | Lowered |
| Feb 7, 2023 | Non-GAAP Research and development expenses (3) | FY2023 | $1.49B – $1.52B | New |
| Feb 7, 2023 | Non-GAAP Selling, general and administrative expenses (3) | FY2023 | $965.00M – $1.06B | Lowered |
| Feb 7, 2023 | Jakafi net product revenues | FY2023 | $2.53B – $2.63B | New |
| Feb 7, 2023 | Other Hematology/Oncology net product revenues (1) | FY2023 | $215.00M – $225.00M | Lowered |
| Nov 1, 2022 | GAAP Cost of product revenues | FY2022 | 6% – 7% | Reaffirmed |
| Nov 1, 2022 | Non-GAAP Cost of product revenues | FY2022 | 5% – 6% | Reaffirmed |
| Nov 1, 2022 | GAAP Research and development expenses | FY2022 | $1.55B – $1.59B | Raised |
| Nov 1, 2022 | GAAP Selling, general and administrative expenses | FY2022 | $950.00M – $1.00B | Lowered |
| Nov 1, 2022 | Non-GAAP Research and development expenses | FY2022 | $1.42B – $1.46B | Raised |
| Nov 1, 2022 | Non-GAAP Selling, general and administrative expenses | FY2022 | $880.00M – $925.00M | Lowered |
| Nov 1, 2022 | Jakafi net product revenues | FY2022 | $2.38B – $2.40B | Raised |
| Nov 1, 2022 | Other Hematology/Oncology net product revenues | FY2022 | $200.00M – $210.00M | Lowered |
| Aug 2, 2022 | GAAP Cost of product revenues | FY2022 | 6% – 7% | Reaffirmed |
| Aug 2, 2022 | Non-GAAP Cost of product revenues (2) | FY2022 | 5% – 6% | Reaffirmed |
| Aug 2, 2022 | GAAP Research and development expenses | FY2022 | $1.55B – $1.59B | Raised |
| Aug 2, 2022 | GAAP Selling, general and administrative expenses | FY2022 | $950.00M – $1.00B | Lowered |
| Aug 2, 2022 | Non-GAAP Research and development expenses (3) | FY2022 | $1.42B – $1.46B | Raised |
| Aug 2, 2022 | Non-GAAP Selling, general and administrative expenses (3) | FY2022 | $880.00M – $925.00M | Lowered |
| Aug 2, 2022 | Jakafi net product revenues | FY2022 | $2.36B – $2.40B | Raised |
| Aug 2, 2022 | Other Hematology/Oncology net product revenues (1) | FY2022 | $210.00M – $240.00M | Lowered |
| May 3, 2022 | GAAP Cost of product revenues | FY2022 | 6% – 7% | Reaffirmed |
| May 3, 2022 | Non-GAAP Cost of product revenues | FY2022 | 5% – 6% | Reaffirmed |
| May 3, 2022 | GAAP Research and development expenses | FY2022 | $1.55B – $1.59B | Raised |
| May 3, 2022 | GAAP Selling, general and administrative expenses | FY2022 | $950.00M – $1.00B | Lowered |
| May 3, 2022 | Non-GAAP Research and development expenses | FY2022 | $1.42B – $1.46B | Raised |
| May 3, 2022 | Non-GAAP Selling, general and administrative expenses | FY2022 | $880.00M – $925.00M | Lowered |
| May 3, 2022 | Jakafi net product revenues | FY2022 | $2.33B – $2.40B | Raised |
| May 3, 2022 | Other Hematology/Oncology net product revenues | FY2022 | $210.00M – $240.00M | Lowered |
| Feb 8, 2022 | GAAP Cost of product revenues | FY2022 | 6% – 7% | New |
| Feb 8, 2022 | Non-GAAP Cost of product revenues (2) | FY2022 | 5% – 6% | New |
| Feb 8, 2022 | GAAP Research and development expenses | FY2022 | $1.55B – $1.59B | New |
| Feb 8, 2022 | GAAP Selling, general and administrative expenses | FY2022 | $950.00M – $1.00B | Lowered |
| Feb 8, 2022 | Non-GAAP Research and development expenses (3) | FY2022 | $1.42B – $1.46B | New |
| Feb 8, 2022 | Non-GAAP Selling, general and administrative expenses (3) | FY2022 | $880.00M – $925.00M | Lowered |
| Feb 8, 2022 | Jakafi net product revenues | FY2022 | $2.30B – $2.40B | New |
| Feb 8, 2022 | Other Hematology/Oncology net product revenues (1) | FY2022 | $210.00M – $240.00M | Lowered |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Incyte filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results